Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8129113 | 0.98 | KMT2A (0.51) | KMT2AGAAALDH1A1EPHX2L3MBTL1 | |
| SCHEMBL10310225 | 0.86 | KMT2A (0.59) | KMT2AGAAALDH1A1EPHX2L3MBTL1 | |
| SCHEMBL14868245 | 0.84 | RAB9A (0.43) | KMT2AGAAALDH1A1EPHX2L3MBTL1 | |
| SCHEMBL10591725 | 0.83 | KMT2A (0.65) | KMT2AGAAALDH1A1EPHX2L3MBTL1 | |
| SCHEMBL14868617 | 0.82 | ALDH1A1 (0.48) | KMT2AGAAALDH1A1EPHX2L3MBTL1 | |
| SCHEMBL14868618 | 0.80 | KMT2A (0.47) | KMT2AGAAALDH1A1EPHX2POLB | |
| SCHEMBL13584238 | 0.80 | ALDH1A1 (0.46) | KMT2AGAAALDH1A1EPHX2L3MBTL1 | |
| SCHEMBL14595477 | 0.79 | KMT2A (0.51) | KMT2AGAAALDH1A1EPHX2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL13584105 | 0.78 | ALDH1A1 (0.44) | KMT2AGAAALDH1A1EPHX2L3MBTL1 | |
| SCHEMBL14703467 | 0.76 | HTT (0.56) | KMT2AGAAALDH1A1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277255-A1 | BIGUANIDE COMPOUND AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. | 2020-09-03 | — | — | US | claimed |
| US-20180044283-A1 | BIGUANIDE COMPOUND AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2018-02-15 | — | — | US | claimed |
| EP-3222614-A2 | BIGUANIDE COMPOUND AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-09-27 | — | — | EP | claimed |
| US-20040063780-A1 | Pharmaceutical preparations for treatment of type II diabetes and methods for treatment of type II diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-04-01 | — | — | US | claimed |
| CN-1281450-A | Substituted 2, 4-diamino-1, 3, 5-triazines and their use as herbicides | BAYER AG (DE) | 2001-01-24 | — | — | CN | claimed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11572341-B2 | Biguanide compound and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572341-B2 | Biguanide compound and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200277255-A1 | BIGUANIDE COMPOUND AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. | 2020-09-03 | — | — | US | disclosed |
| WO-2013103384-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20040063780-A1 | Pharmaceutical preparations for treatment of type II diabetes and methods for treatment of type II diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-04-01 | — | — | US | disclosed |
| US-6348435-B1 | Substituted 2,4-diamino-1,3,5-triazine and their use as herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2002-02-19 | — | — | US | disclosed |
| CN-1281450-A | Substituted 2, 4-diamino-1, 3, 5-triazines and their use as herbicides | BAYER AG (DE) | 2001-01-24 | — | — | CN | disclosed |
| EP-1021441-A1 | SUBSTITUTED 2,4-DIAMINO-1,3,5-TRIAZINE AND THEIR USE AS HERBICIDES | BAYER AG (DE) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999018100-A1 | SUBSTITUTED 2,4-DIAMINO-1,3,5-TRIAZINE AND THEIR USE AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | KMT2A 2239/4885GAA 54/4885ALDH1A1 980/4885 |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | KMT2A 2239/4885GAA 54/4885ALDH1A1 980/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | KMT2A 2239/4885GAA 54/4885ALDH1A1 980/4885 |
| US-20180044283-A1 | BIGUANIDE COMPOUND AND USE THEREOF | MKI67, GCG, GCKR | KMT2A 2277/4885GAA 788/4885ALDH1A1 1098/4885 |
| US-11572341-B2 | Biguanide compound and use thereof | MKI67, GCG, GCKR | KMT2A 2277/4885GAA 788/4885ALDH1A1 1098/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | KMT2A 2239/4885GAA 54/4885ALDH1A1 980/4885 |
| US-20040063780-A1 | Pharmaceutical preparations for treatment of type II diabetes and methods for treatment of type II diabetes | SLC5A2, SLC5A1, IAPP | KMT2A 3538/4885GAA 746/4885ALDH1A1 1406/4885 |
| US-20200277255-A1 | BIGUANIDE COMPOUND AND USE THEREOF | MKI67, GCG, GCKR | KMT2A 2277/4885GAA 788/4885ALDH1A1 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.